Preclinical evidence has supported the utility of 5‐HT1AR antagonists for treating cognitive impairments associated with AD, which is likely due to facilitation of glutamatergic transmission by removal of the inhibitory effects of 5‐HT (Dijk et al., 1995; Schechter et al., 2005). Here, HTR5A is linked to Alzheimer disease.